Does the media favor TMDX or BBNX?

In the previous week, Beta Bionics had 40 more articles in the media than TransMedics Group. MarketBeat recorded 54 mentions for Beta Bionics and 14 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.52 beat Beta Bionics' score of 0.07 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 3 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beta Bionics 5 Very Positive mention(s) 1 Positive mention(s) 41 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, ATRC or BBNX?

AtriCure has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $534.53M 5.27 -$11.45M $0.21 263.70 Beta Bionics $119.01M 6.67 -$73.20M -$1.65 N/A

Is ATRC or BBNX more profitable?

AtriCure has a net margin of 1.85% compared to Beta Bionics' net margin of -61.31%. AtriCure's return on equity of 2.34% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets AtriCure 1.85% 2.34% 1.77% Beta Bionics -61.31% -26.30% -23.25%

Does the media refer more to ATRC or BBNX?

In the previous week, Beta Bionics had 40 more articles in the media than AtriCure. MarketBeat recorded 54 mentions for Beta Bionics and 14 mentions for AtriCure. AtriCure's average media sentiment score of 0.84 beat Beta Bionics' score of 0.07 indicating that AtriCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 7 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beta Bionics 5 Very Positive mention(s) 1 Positive mention(s) 41 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, AXGN or BBNX?

AxoGen has higher revenue and earnings than Beta Bionics. AxoGen is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 10.46 -$15.70M -$0.68 N/A Beta Bionics $119.01M 6.67 -$73.20M -$1.65 N/A

Is AXGN or BBNX more profitable?

AxoGen has a net margin of -13.36% compared to Beta Bionics' net margin of -61.31%. AxoGen's return on equity of -8.90% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.36% -8.90% -6.47% Beta Bionics -61.31% -26.30% -23.25%

Does the media favor AXGN or BBNX?

In the previous week, Beta Bionics had 42 more articles in the media than AxoGen. MarketBeat recorded 54 mentions for Beta Bionics and 12 mentions for AxoGen. AxoGen's average media sentiment score of 0.41 beat Beta Bionics' score of 0.07 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Beta Bionics 5 Very Positive mention(s) 1 Positive mention(s) 41 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ESTA or BBNX?

In the previous week, Beta Bionics had 49 more articles in the media than Establishment Labs. MarketBeat recorded 54 mentions for Beta Bionics and 5 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.83 beat Beta Bionics' score of 0.07 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Beta Bionics 5 Very Positive mention(s) 1 Positive mention(s) 41 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, BBNX or NVCR?

Beta Bionics has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Beta Bionics $119.01M 6.67 -$73.20M -$1.65 N/A NovoCure $655.35M 2.86 -$136.23M -$1.30 N/A

Is BBNX or NVCR more profitable?

NovoCure has a net margin of -21.25% compared to Beta Bionics' net margin of -61.31%. Beta Bionics' return on equity of -26.30% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets Beta Bionics -61.31% -26.30% -23.25% NovoCure -21.25% -44.00% -15.85%

Does the media prefer BBNX or NVCR?

In the previous week, Beta Bionics had 49 more articles in the media than NovoCure. MarketBeat recorded 54 mentions for Beta Bionics and 5 mentions for NovoCure. NovoCure's average media sentiment score of 0.74 beat Beta Bionics' score of 0.07 indicating that NovoCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 5 Very Positive mention(s) 1 Positive mention(s) 41 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral NovoCure 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Beta Bionics (BBNX) Competitors

$17.66 +0.93 (+5.53%)

As of 11:00 AM Eastern

Compare

BBNX vs. TMDX, ATRC, AXGN, ESTA, and NVCR

Should you buy Beta Bionics stock or one of its competitors? Beta Bionics's main competitors and comparable companies include TransMedics Group (TMDX), AtriCure (ATRC), AxoGen (AXGN), Establishment Labs (ESTA), and NovoCure (NVCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Beta Bionics compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and Beta Bionics (NASDAQ:BBNX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

TransMedics Group has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$668.47M	4.58	$190.29M	$3.89	22.77
Beta Bionics	$119.01M	6.67	-$73.20M	-$1.65	N/A

99.7% of TransMedics Group shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by company insiders. Comparatively, 5.3% of Beta Bionics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Beta Bionics had 40 more articles in the media than TransMedics Group. MarketBeat recorded 54 mentions for Beta Bionics and 14 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.52 beat Beta Bionics' score of 0.07 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	3 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beta Bionics	5 Very Positive mention(s)	1 Positive mention(s)	41 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

TransMedics Group currently has a consensus price target of $124.18, indicating a potential upside of 40.17%. Beta Bionics has a consensus price target of $21.00, indicating a potential upside of 18.94%. Given TransMedics Group's higher possible upside, equities research analysts clearly believe TransMedics Group is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

TransMedics Group has a net margin of 22.69% compared to Beta Bionics' net margin of -61.31%. TransMedics Group's return on equity of 15.88% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	22.69%	15.88%	5.95%
Beta Bionics	-61.31%	-26.30%	-23.25%

TransMedics Group has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.37, indicating that its share price is 237% more volatile than the broader market.

Summary

TransMedics Group beats Beta Bionics on 11 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to AtriCure?

AtriCure (NASDAQ:ATRC) and Beta Bionics (NASDAQ:BBNX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

AtriCure has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.37, suggesting that its stock price is 237% more volatile than the broader market.

AtriCure has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	5.27	-$11.45M	$0.21	263.70
Beta Bionics	$119.01M	6.67	-$73.20M	-$1.65	N/A

In the previous week, Beta Bionics had 40 more articles in the media than AtriCure. MarketBeat recorded 54 mentions for Beta Bionics and 14 mentions for AtriCure. AtriCure's average media sentiment score of 0.84 beat Beta Bionics' score of 0.07 indicating that AtriCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	7 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beta Bionics	5 Very Positive mention(s)	1 Positive mention(s)	41 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

AtriCure presently has a consensus price target of $52.00, indicating a potential downside of 6.10%. Beta Bionics has a consensus price target of $21.00, indicating a potential upside of 18.94%. Given Beta Bionics' higher probable upside, analysts plainly believe Beta Bionics is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

99.1% of AtriCure shares are owned by institutional investors. 4.0% of AtriCure shares are owned by company insiders. Comparatively, 5.3% of Beta Bionics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

AtriCure has a net margin of 1.85% compared to Beta Bionics' net margin of -61.31%. AtriCure's return on equity of 2.34% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
Beta Bionics	-61.31%	-26.30%	-23.25%

Summary

AtriCure beats Beta Bionics on 11 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to AxoGen?

AxoGen (NASDAQ:AXGN) and Beta Bionics (NASDAQ:BBNX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

AxoGen has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.37, meaning that its share price is 237% more volatile than the broader market.

AxoGen has higher revenue and earnings than Beta Bionics. AxoGen is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	10.46	-$15.70M	-$0.68	N/A
Beta Bionics	$119.01M	6.67	-$73.20M	-$1.65	N/A

In the previous week, Beta Bionics had 42 more articles in the media than AxoGen. MarketBeat recorded 54 mentions for Beta Bionics and 12 mentions for AxoGen. AxoGen's average media sentiment score of 0.41 beat Beta Bionics' score of 0.07 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beta Bionics	5 Very Positive mention(s)	1 Positive mention(s)	41 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

80.3% of AxoGen shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Comparatively, 5.3% of Beta Bionics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

AxoGen has a net margin of -13.36% compared to Beta Bionics' net margin of -61.31%. AxoGen's return on equity of -8.90% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
Beta Bionics	-61.31%	-26.30%	-23.25%

AxoGen presently has a consensus target price of $51.56, indicating a potential upside of 17.64%. Beta Bionics has a consensus target price of $21.00, indicating a potential upside of 18.94%. Given Beta Bionics' higher probable upside, analysts clearly believe Beta Bionics is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

AxoGen beats Beta Bionics on 11 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and Beta Bionics (NASDAQ:BBNX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Establishment Labs has a net margin of -15.82% compared to Beta Bionics' net margin of -61.31%. Beta Bionics' return on equity of -26.30% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-15.82%	-196.69%	-10.73%
Beta Bionics	-61.31%	-26.30%	-23.25%

Establishment Labs has higher revenue and earnings than Beta Bionics. Establishment Labs is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$245.82M	8.53	-$51.06M	-$1.31	N/A
Beta Bionics	$119.01M	6.67	-$73.20M	-$1.65	N/A

Establishment Labs currently has a consensus target price of $100.25, suggesting a potential upside of 42.49%. Beta Bionics has a consensus target price of $21.00, suggesting a potential upside of 18.94%. Given Establishment Labs' stronger consensus rating and higher possible upside, analysts clearly believe Establishment Labs is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

72.9% of Establishment Labs shares are held by institutional investors. 10.0% of Establishment Labs shares are held by company insiders. Comparatively, 5.3% of Beta Bionics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Beta Bionics had 49 more articles in the media than Establishment Labs. MarketBeat recorded 54 mentions for Beta Bionics and 5 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.83 beat Beta Bionics' score of 0.07 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Beta Bionics	5 Very Positive mention(s)	1 Positive mention(s)	41 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Establishment Labs has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.37, indicating that its stock price is 237% more volatile than the broader market.

Summary

Establishment Labs beats Beta Bionics on 12 of the 16 factors compared between the two stocks.

How does Beta Bionics compare to NovoCure?

Beta Bionics (NASDAQ:BBNX) and NovoCure (NASDAQ:NVCR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

In the previous week, Beta Bionics had 49 more articles in the media than NovoCure. MarketBeat recorded 54 mentions for Beta Bionics and 5 mentions for NovoCure. NovoCure's average media sentiment score of 0.74 beat Beta Bionics' score of 0.07 indicating that NovoCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	5 Very Positive mention(s)	1 Positive mention(s)	41 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
NovoCure	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Beta Bionics has a beta of 3.37, suggesting that its stock price is 237% more volatile than the broader market. Comparatively, NovoCure has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

NovoCure has a net margin of -21.25% compared to Beta Bionics' net margin of -61.31%. Beta Bionics' return on equity of -26.30% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-61.31%	-26.30%	-23.25%
NovoCure	-21.25%	-44.00%	-15.85%

Beta Bionics presently has a consensus price target of $21.00, suggesting a potential upside of 18.94%. NovoCure has a consensus price target of $21.20, suggesting a potential upside of 31.60%. Given NovoCure's higher possible upside, analysts plainly believe NovoCure is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
NovoCure	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

84.6% of NovoCure shares are owned by institutional investors. 5.3% of Beta Bionics shares are owned by company insiders. Comparatively, 6.6% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Beta Bionics has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$119.01M	6.67	-$73.20M	-$1.65	N/A
NovoCure	$655.35M	2.86	-$136.23M	-$1.30	N/A

Summary

Beta Bionics and NovoCure tied by winning 8 of the 16 factors compared between the two stocks.

Get Beta Bionics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBNX vs. The Competition

Export

Metric	Beta Bionics	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$792.68M	$5.39B	$7.15B	$14.21B
Dividend Yield	N/A	1.80%	2.57%	11.71%
P/E Ratio	-10.68	24.87	273.46	25.34
Price / Sales	6.67	83.09	670.93	98.74
Price / Cash	N/A	33.03	28.42	34.96
Price / Book	2.70	5.99	10.43	6.20
Net Income	-$73.20M	$149.33M	$3.48B	$357.95M
7 Day Performance	-8.66%	-1.81%	-1.90%	-1.21%
1 Month Performance	0.49%	-3.67%	-0.14%	-3.22%
1 Year Performance	-30.24%	9.21%	19.12%	6.27%

Beta Bionics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBNX Beta Bionics	2.0904 of 5 stars	$17.66 +5.5%	$20.60 +16.7%	-36.7%	$792.68M	$119.01M	N/A	423	Trending News Analyst Forecast Gap Down
TMDX TransMedics Group	4.3529 of 5 stars	$89.98 +3.4%	$124.18 +38.0%	-25.1%	$3.01B	$605.49M	23.13	210	Insider Trade
ATRC AtriCure	2.2612 of 5 stars	$51.52 -1.8%	$52.00 +0.9%	+59.1%	$2.67B	$534.53M	245.35	1,300	Insider Trade
AXGN AxoGen	2.504 of 5 stars	$48.28 +2.5%	$51.56 +6.8%	+166.8%	$2.53B	$225.21M	N/A	450	Positive News
ESTA Establishment Labs	3.0781 of 5 stars	$74.29 +2.8%	$100.25 +34.9%	+91.9%	$2.15B	$211.08M	N/A	1,004	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBNX) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Beta Bionics (BBNX) Competitors

BBNX vs. TMDX, ATRC, AXGN, ESTA, and NVCR

How does Beta Bionics compare to TransMedics Group?

Summary

How does Beta Bionics compare to AtriCure?

Summary

How does Beta Bionics compare to AxoGen?

Summary

How does Beta Bionics compare to Establishment Labs?

Summary

How does Beta Bionics compare to NovoCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX vs. The Competition

Beta Bionics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Beta Bionics (BBNX) Competitors

BBNX vs. TMDX, ATRC, AXGN, ESTA, and NVCR

How does Beta Bionics compare to TransMedics Group?

Which has higher valuation and earnings, TMDX or BBNX?

Do institutionals and insiders believe in TMDX or BBNX?

Does the media favor TMDX or BBNX?

Do analysts prefer TMDX or BBNX?

Is TMDX or BBNX more profitable?

Which has more risk and volatility, TMDX or BBNX?

Summary

How does Beta Bionics compare to AtriCure?

Which has more volatility & risk, ATRC or BBNX?

Which has better earnings and valuation, ATRC or BBNX?

Does the media refer more to ATRC or BBNX?

Do analysts rate ATRC or BBNX?

Do insiders & institutionals believe in ATRC or BBNX?

Is ATRC or BBNX more profitable?

Summary

How does Beta Bionics compare to AxoGen?

Which has more risk & volatility, AXGN or BBNX?

Which has better valuation & earnings, AXGN or BBNX?

Does the media favor AXGN or BBNX?

Do insiders and institutionals believe in AXGN or BBNX?

Is AXGN or BBNX more profitable?

Do analysts recommend AXGN or BBNX?

Summary

How does Beta Bionics compare to Establishment Labs?

Is ESTA or BBNX more profitable?

Which has better valuation and earnings, ESTA or BBNX?

Do analysts rate ESTA or BBNX?

Do institutionals & insiders hold more shares of ESTA or BBNX?

Does the media favor ESTA or BBNX?

Which has more risk & volatility, ESTA or BBNX?

Summary

How does Beta Bionics compare to NovoCure?

Does the media prefer BBNX or NVCR?

Which has more risk and volatility, BBNX or NVCR?

Is BBNX or NVCR more profitable?

Do analysts rate BBNX or NVCR?

Do institutionals and insiders hold more shares of BBNX or NVCR?

Which has better earnings & valuation, BBNX or NVCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX vs. The Competition

Beta Bionics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools